A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients With Severe Asthma.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs GSK 679586 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 Mar 2012 This trial is recruiting in Netherlands and France.
- 11 Mar 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.